Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/19 08:25:50 am
449.6 DKK   +2.36%
01/18NOVO NORDISK : Buy rating from JP Morgan
MD
01/15NOVO NORDISK A/S : Deutsche Bank Initiates Coverage on Novo Nordisk A/S With Buy Rating
MT
01/15European ADRs Move Sharply Lower in Friday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

NOVO NORDISK : UBS reiterates its Neutral rating

11/09/2020 | 08:59am EST

Michael Leuchten from UBS retains his Neutral opinion on the stock. The target price remains set at DKK 415.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
NOVO NORDISK A/S 2.41% 450 Delayed Quote.2.95%
UBS GROUP AG -0.97% 13.29 Delayed Quote.7.58%
All news about NOVO NORDISK A/S
01/18NOVO NORDISK : Buy rating from JP Morgan
MD
01/15NOVO NORDISK A/S : Deutsche Bank Initiates Coverage on Novo Nordisk A/S With Buy..
MT
01/15European ADRs Move Sharply Lower in Friday Trading
MT
01/15PRESS RELEASE : BP p.l.c.: BP announces non-executive director resignation
DJ
01/15NOVO NORDISK : Buy rating by Deutsche Bank
MD
01/11NOVO NORDISK A/S : – Share repurchase programme
AQ
01/11ZUR ROSE : Joins Novo Nordisk to Offer Health Services for Obese People
MT
01/07WERNER LANTHALER : Evotec to attend upcoming investor conferences
DJ
01/06European ADRs Climb Sharply Higher in Wednesday Trading
MT
01/06DICERNA PHARMACEUTICALS : Announces Novo Nordisk's Nomination of First Candidate..
AQ
More news
Financials
Sales 2020 127 B 20 676 M 20 676 M
Net income 2020 42 089 M 6 856 M 6 856 M
Net cash 2020 7 191 M 1 171 M 1 171 M
P/E ratio 2020 24,3x
Yield 2020 2,04%
Capitalization 1 015 B 165 B 165 B
EV / Sales 2020 7,94x
EV / Sales 2021 7,50x
Nbr of Employees 44 326
Free-Float 75,1%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 452,78 DKK
Last Close Price 439,25 DKK
Spread / Highest target 25,2%
Spread / Average Target 3,08%
Spread / Lowest Target -30,6%
EPS Revisions
Managers and Directors
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S2.95%164 819
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG1.93%303 276
NOVARTIS AG1.65%217 178
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993